INNT Innovate Biopharmaceuticals Inc.

0.56
-0.02  -3%
Previous Close 0.58
Open 0.54
Price To Book -6.22
Market Cap 20,095,014
Shares 35,883,953
Volume 606,310
Short Ratio
Av. Daily Volume 875,456
Stock charts supplied by TradingView

NewsSee all news

  1. Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts for the 2020 Digestive Disease Week (DDW) Conference

    Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory DiseasesRALEIGH, NC / ACCESSWIRE / February 19, 2020 / Innovate

  2. Innovate Biopharmaceuticals Announces Shareholder Approval of All Proposals in Connection with the Pending Merger with RDD Pharma Ltd. to Create 9 Meters Biopharma, a GI-focused Platform Company

    Closing of this transformative transaction expected in early Q2 2020 upon completion of remaining closing conditions and receipt of regulatory approval in IsraelRALEIGH, NC / ACCESSWIRE / February 18, 2020 / Innovate

  3. RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline

    TEL AVIV, Israel and RICHMOND, Calif., Nov. 13, 2019 /PRNewswire/ -- RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter

  4. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 planned.
INN-108
Ulcerative colitis
Phase 3 initiation of dosing announced August 13, 2019.
INN-202
Celiac disease
Phase 2 to be initiated in 2019.
Larazotide acetate
Nonalcoholic steatohepatitis (NASH)

Latest News

  1. Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts for the 2020 Digestive Disease Week (DDW) Conference

    Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory DiseasesRALEIGH, NC / ACCESSWIRE / February 19, 2020 / Innovate

  2. Innovate Biopharmaceuticals Announces Shareholder Approval of All Proposals in Connection with the Pending Merger with RDD Pharma Ltd. to Create 9 Meters Biopharma, a GI-focused Platform Company

    Closing of this transformative transaction expected in early Q2 2020 upon completion of remaining closing conditions and receipt of regulatory approval in IsraelRALEIGH, NC / ACCESSWIRE / February 18, 2020 / Innovate

  3. RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline

    TEL AVIV, Israel and RICHMOND, Calif., Nov. 13, 2019 /PRNewswire/ -- RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter

  4. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company